ThirdAge Ulcerative Colitis Med Meets Clinical Goals for Children ThirdAge The drug is too approved for utilization in treatment for autoimmune disorders specified as rheumatoid arthritis, plaque psoriasis and Crohn's disease. Remicade prompted a effect in 73 per centum of patients between the ages of 6 and xvii years old after eight weeks ... J&J's Remicade meets ulcerative colitis examination goal BusinessWeek Centocor's Remicade Achieves state of matter III Success Against Pediatric Ulcerative ... Genetic Engineering tidings New Phase iii Study Results amusement REMICADE® is effectual in the attention of ... Pr Newswire (press release) all 25 tidings articles » Link To Article
No comments:
Post a Comment